1. Introduction
rhinitis, Allergic rhinitis, DLE, allergic diseases
DISEASE, ALLERGIC RHINITIS, RHINOCONJUNCTIVITIS, RHINITIS, DLE
Allergic rhinitis (AR) has considerable impact on the general health of individuals. Therefore, treatment trials should include an evaluation of quality of life. We aimed to determine changes in the quality of life of moderate/severe AR patients treated with standard treatment in addition to dialyzable leukocyte extract (DLE), a peptide-based immunomodulator. In a prospective, non-controlled trial, DLE was added to the standard treatment regimen for patients with moderate/severe AR. DLE was administered orally at 2 mg per day for 5 days, followed by 4 mg per week for 5 weeks, and then 2 mg per week for 5 weeks. The primary endpoints were overall improved Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores, domain scores, and individual item scores of 0.5 points or higher. Statistical significance was defined as Clinical trials registration ID: NCT02506998Allergic rhinitis (AR) is a common disease worldwide.Although not life-threatening, AR considerably affects general well-being, absenteeism, work, and school performance.The T-helper cell balance in allergic diseases is skewed toward a Th2/Th17 response, and it has been proposed that Th1/Treg cytokines play a negative regulatory role in Th2 inflammatory predominance.This study aimed to determine changes in QoL of patients with moderate/severe AR, treated with standard treatment in addition to DLE.